Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Immvira Bio Files for Hong Kong IPO with Phase II Oncolytic Immunotherapy MVR-T3011

Fineline Cube Jan 15, 2026
Company Deals

Exegenesis Bio Files for Hong Kong IPO with AI-Powered Gene Therapy Pipeline

Fineline Cube Jan 15, 2026
Company Deals

QYuns’ QX030N Partner Caldera Raises $112.5 Million for IBD Bispecific

Fineline Cube Jan 15, 2026
Company Deals

NVIDIA and Eli Lilly Launch $1 Billion AI Co‑Innovation Lab to Transform Drug Development

Fineline Cube Jan 14, 2026
Company Deals

AstraZeneca Acquires Modella AI to Embed Multi‑Modal Foundation Models in Oncology R&D

Fineline Cube Jan 14, 2026
Policy / Regulatory

NHSA Launches 6th VBP Tender for Medical Consumables in China, Targeting Drug-Coated Balloons

Fineline Cube Jan 13, 2026
Company Drug

J&J’s TECVAYLI Shows 71% PFS Reduction in Phase 3 MajesTEC‑9 for Multiple Myeloma

Fineline Cube Jan 15, 2026
Company Drug

Leads Biolabs’ Opamtistomig Secures FDA Fast Track for EP-NEC as First 4-1BB Bispecific

Fineline Cube Jan 15, 2026
Company Drug

Boehringer Ingelheim Gets NMPA Approval for Brigimadlin Safety and Efficacy Study in China

Fineline Cube Sep 14, 2023

Germany-based Boehringer Ingelheim (BI) has announced that it has received approval from the National Medical...

Policy / Regulatory

NHSA Unveils Measures to Enhance Smart Monitoring and Auditing of Basic Medical Insurance Funds

Fineline Cube Sep 14, 2023

The National Healthcare Security Administration (NHSA) has released a notification detailing planned measures to improve...

Company Drug

MSD’s Sotatercept Demonstrates Positive Interim Results in Phase III PAH Studies

Fineline Cube Sep 13, 2023

Merck, Sharp & Dohme (MSD; NYSE: MRK) has presented interim data from Phase III and...

Company Deals

Suzhou Porton Biologics Partners with BRL Medicine to Advance Gene and Cell Therapy Pipeline

Fineline Cube Sep 13, 2023

China-based Contract Development and Manufacturing Organization (CDMO) Suzhou Porton Biologics Ltd has entered into a...

Company Drug

AstraZeneca’s Tagrisso Combination Therapy Shows Improved Efficacy in EGFR-mutated NSCLC

Fineline Cube Sep 13, 2023

UK-headquartered AstraZeneca (AZ; NASDAQ: AZN) has announced interim Phase III data demonstrating that the addition...

Company Deals

Jiangsu Recbio and Yikang Biological Partner to Develop RSV Preventative Vaccine

Fineline Cube Sep 13, 2023

Jiangsu Recbio Technology Co., Ltd, a China-based biotechnology company, has entered into a product development...

Company Drug

Janssen Reports Positive Results from Phase Ib/II Study of Rybrevant Combo in EGFR-mutated NSCLC

Fineline Cube Sep 13, 2023

Johnson & Johnson (J&J; NYSE: JNJ) subsidiary Janssen has provided an update on an ongoing...

Company Drug

AstraZeneca’s Enhertu Shows Promising Results in Phase II HER2-mutant NSCLC Trial

Fineline Cube Sep 13, 2023

AstraZeneca (AZ; NASDAQ: AZN) has released early data from a Phase II trial investigating the...

Company Deals

Innovent Biologics Plans Share Placement to Raise HKD 2.36 Billion for Global Expansion

Fineline Cube Sep 13, 2023

China-based biotech Innovent Biologics Inc., (HKG: 1801) has issued a notice stating its intention to...

Policy / Regulatory

NMPA Pilots Priority Review for Rare Disease Formula Foods, Aims to Reduce Approval Time

Fineline Cube Sep 13, 2023

The National Medical Products Administration (NMPA) has initiated a pilot program to implement “Priority review...

Company Medical Device

Huadong Medicine’s Subsidiary Viora Ltd’s V20 Accepted for NMPA Review

Fineline Cube Sep 13, 2023

China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that the National Medical Products Administration...

Company Drug

Gan & Lee Pharmaceuticals Initiates Phase II Clinical Study for Weekly Insulin GZR4

Fineline Cube Sep 13, 2023

Gan & Lee Pharmaceuticals (SHA: 603087), a China-based pharmaceutical company, has announced the dosing of...

Company Drug

Grand Pharmaceutical Receives NMPA Approval for Generic Carbaglu for Hyperammonemia Treatment

Fineline Cube Sep 13, 2023

China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced that it has received marketing approval...

Company Deals

JW Therapeutics and 2seventy Bio Expand Partnership for Cell Therapy Development

Fineline Cube Sep 13, 2023

China-based cell therapy firm JW Therapeutics (HKG: 2126) and US biotech 2seventy Bio Inc., (NASDAQ:...

Company Deals

Wuhan YZY Biopharma Aims to Raise HKD 220 Million in Hong Kong IPO

Fineline Cube Sep 13, 2023

Wuhan YZY Biopharma Co., Ltd, (HKG: 2496) a biopharmaceutical company specializing in targeted cancer drugs...

Company Deals

Exelixis Secures Global Rights to Develop Insilico Medicine’s USP1 Inhibitor ISM3091

Fineline Cube Sep 13, 2023

China-based generative artificial intelligence (AI)-driven biotech Insilico Medicine has entered into an exclusive license agreement...

Company Medical Device

Burning Rock’s CanCatch MRD Product Shows Superiority in Postoperative NSCLC Monitoring

Fineline Cube Sep 13, 2023

China-based medtech firm Burning Rock Ltd (NASDAQ: BNR) has revealed positive findings from a five-year...

Company Drug

Clover Biopharmaceuticals Launches AdimFlu-S, the Only Imported Quadrivalent Influenza Vaccine in China

Fineline Cube Sep 12, 2023

China-based Clover Biopharmaceuticals Ltd., (HKG: 2197) has announced the launch of AdimFlu-S (QIS) in mainland...

Company Drug

HutchMed Advances Tazverik Phase II Trial for Follicular Lymphoma in China

Fineline Cube Sep 12, 2023

China-based HutchMed (HKG: 0013, NASDAQ: HCM) has announced the completion of patient enrollment in a...

Company Drug

Hybio Pharmaceutical’s Semaglutide Clinical Trial Filing Accepted by China’s NMPA

Fineline Cube Sep 12, 2023

China-based Hybio Pharmaceutical Co., Ltd (SHE: 300199) has announced that the National Medical Products Administration...

Posts pagination

1 … 417 418 419 … 609

Recent updates

  • J&J’s TECVAYLI Shows 71% PFS Reduction in Phase 3 MajesTEC‑9 for Multiple Myeloma
  • Immvira Bio Files for Hong Kong IPO with Phase II Oncolytic Immunotherapy MVR-T3011
  • Exegenesis Bio Files for Hong Kong IPO with AI-Powered Gene Therapy Pipeline
  • Sunshine Lake Pharma Launches AI-Powered PROTAC Platform to Target Undruggable Proteins
  • QYuns’ QX030N Partner Caldera Raises $112.5 Million for IBD Bispecific
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

J&J’s TECVAYLI Shows 71% PFS Reduction in Phase 3 MajesTEC‑9 for Multiple Myeloma

Company Deals

Immvira Bio Files for Hong Kong IPO with Phase II Oncolytic Immunotherapy MVR-T3011

Company Deals

Exegenesis Bio Files for Hong Kong IPO with AI-Powered Gene Therapy Pipeline

Company Digital

Sunshine Lake Pharma Launches AI-Powered PROTAC Platform to Target Undruggable Proteins

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.